Tyk Medicines Inc. has patented new cyclin-dependent kinase 2 (CDK2) and/or cyclin-dependent kinase 4 (CDK4) inhibitors reported to be useful for the treatment of cancer, infections, metabolic ...

Posting $162 million in fourth-quarter net sales, a 48% increase, and $508 million for the whole yeara 50% riseOpzelura ...

Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D ...

Corporation, a biopharmaceutical company specializing in the discovery, development, and commercialization of proprietary ...

The workforce reduction is expected to be substantially completed in the second quarter of 2025.

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. Moana's island home of ...

This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...

Corporation, a biopharmaceutical company specializing in proprietary therapeutics with a market capitalization of $14 billion, finds itself at a critical juncture as it navigates a robust pipeline ...

In Georg’s academic lab, research continues apace on selective inhibitors of another non-hormonal male contraceptive target, cyclin-dependent kinase 2 (CDK2). Longer term, her team is also targeting a ...

COLUMBUS, Ind. — A 36-year-old Columbus woman is in the Bartholomew County Jail for preliminary charges of neglect after her child reportedly overdosed on drugs. On Jan. 17th, at 11:50 a.m ...